Ian S. Hagemann

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 29 papers. Top paper: “Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial”.

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1695

N/A

7.0DataRank · unranked

368 citations

Katie M. Campbell, Ann Marie Egloff, Paul Zolkind, Zachary L. Skidmore, Brian Nussenbaum +39 more

Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer

Cancer Discovery(2022)10.1158/2159-8290.cd-22-0200

N/A

2.5DataRank · unranked

140 citations

Eric J. Jaehnig, Karsten Krug, Jonathan T. Lei, Erik J. Bergstrom, Beom-Jun Kim +34 more

Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer

Breast Cancer Research and Treatment(2021)10.1007/s10549-021-06307-3

N/A

1.1DataRank · unranked

35 citations

Ina Chen, Jingqin Luo, Mothaffar F. Rimawi, Ian S. Hagemann, Bryan Fisk +29 more

The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women

Gynecologic Oncology(2021)10.1016/j.ygyno.2020.12.040

N/A

0.941DataRank · unranked

26 citations

Wei Deng, Richard J. Zaino, Matthew A. Powell, Camille C. Gunderson, Casey Cosgrove +15 more

A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN)

npj Breast Cancer(2023)10.1038/s41523-022-00504-z

N/A

0.705DataRank · unranked

23 citations

Donald W. Northfelt, Tracey L. O’Connor, Ellis Levine, Jingqin Luo, Yu Tao +16 more

Immunogenomic Profiling and Pathological Response Results From a Clinical Trial of Docetaxel and Carboplatin in Triple Negative Breast Cancer

Research Square(2021)10.21203/rs.3.rs-420931/v1

N/A

0DataRank · unranked

1 citations

Ina Chen, Jingqin Luo, Mothaffar F. Rimawi, Ian S. Hagemann, Bryan Fisk +29 more

A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013

npj Breast Cancer(2022)10.1038/s41523-022-00500-3

N/A

0DataRank · unranked

54 citations

Feng Gao, Cherease R. Street, Ina Chen, Donald W. Northfelt, Robert Wesolowski +21 more

Quantification of ovarian lesion and fallopian tube vasculature using optical-resolution photoacoustic microscopy

Scientific Reports(2022)10.1038/s41598-022-19778-1

N/A

0DataRank · unranked

7 citations

Sitai Kou, Yixiao Lin, Andrea R. Hagemann, Ian S. Hagemann, Premal H. Thaker +7 more

Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.11.09.515796

N/A

0DataRank · unranked

0 citations

Yirui Sun, Maureen Highkin, Nagalaxmi Vemalapally, Xiaohua Jin, Brandon Zhou +9 more

Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance

Cancer Research(2023)10.1158/0008-5472.can-22-3558

N/A

0DataRank · unranked

33 citations

Yirui Sun, Maureen Highkin, Nagalaxmi Vemalapally, Xiaohua Jin, Brandon Zhou +9 more

Epigenetic reprogramming of cell cycle genes by ACK1 promotes breast cancer resistance to CDK4/6 inhibitor

Oncogene(2023)10.1038/s41388-023-02747-x

N/A

0DataRank · unranked

26 citations

Audrey Wilson, Dhivya Sridaran, Kiran Mahajan, Christopher J. O’Conor, Ian S. Hagemann +8 more

Stromal DDR2 Promotes Ovarian Cancer Metastasis through Regulation of Metabolism and Secretion of Extracellular Matrix Proteins

Molecular Cancer Research(2023)10.1158/1541-7786.mcr-23-0347

N/A

0DataRank · unranked

22 citations

Molly M. Greenwade, Elizabeth Stock, Elena Lomonosova, Kevin Cho, Whitney R. Grither +17 more

Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG-210) study of 311 women

Gynecologic Oncology(2023)10.1016/j.ygyno.2023.08.005

N/A

0DataRank · unranked

10 citations

Wei Deng, Richard J. Zaino, Matthew A. Powell, Camille Gunderson Jackson, Casey Cosgrove +14 more

Characterization of adnexal lesions using photoacoustic imaging to improve sonographic O‐RADS risk assessment

Ultrasound in Obstetrics and Gynecology(2023)10.1002/uog.27452

N/A

0DataRank · unranked

3 citations

Hongbo Luo, William D. Middleton, Malak Itani, Ian S. Hagemann, Andrea R. Hagemann +8 more

Weakly supervised deep learning for predicting the response to hormonal treatment of women with atypical endometrial hyperplasia: a feasibility study

PubMed(2023)10.1117/12.2652912

N/A

0DataRank · unranked

4 citations

Ian S. Hagemann, Kenny Cha, Christopher Trindade, Nicholas Petrick, Nicolas Kostelecky +2 more

Neratinib Synergizes with Trastuzumab Antibody Drug Conjugate or with Vinorelbine to Treat HER2 Mutated Breast Cancer Patient Derived Xenografts and Organoids

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.12.19.572069

N/A

0DataRank · unranked

2 citations

Tina Primeau, Maureen Highkin, Stephanie L. Pratt, Ashley R. Tipton, Nagalaxmi Vemalapally +9 more

Quality of life and survivorship in patients with low-grade ovarian cancer

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.08.010

N/A

0DataRank · unranked

1 citations

Rachel Telles, Michael J. Goodheart, Laila Dahmoush, Ian S. Hagemann, Frank J. Penedo +6 more

End-to-end deep learning method for predicting hormonal treatment response in women with atypical endometrial hyperplasia or endometrial cancer

Journal of Medical Imaging(2024)10.1117/1.jmi.11.1.017502

N/A

0DataRank · unranked

3 citations

Ian S. Hagemann, Kenny H. Cha, Christopher Trindade, Nicholas Petrick, Nicolas Kostelecky +5 more

Enhancing Progestin Therapy with a Glucagon-Like Peptide 1 Agonist for the Conservative Management of Endometrial Cancer

Cancers(2025)10.3390/cancers17040598

N/A

0DataRank · unranked

14 citations

Ian S. Hagemann, David G. Mutch, Eric J. Devor, Paige K. Malmrose, Yuping Zhang +4 more

Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination–proficient ovarian cancer

Journal of Clinical Investigation(2025)10.1172/jci189511

N/A

0DataRank · unranked

7 citations

Amanda Compadre, Rebecca Drexler, Megan Loeb, Kevin Rodriguez, Joshua Brill +22 more

Vascular graph network for ovarian lesion classification using optical-resolution photoacoustic microscopy

Photoacoustics(2025)10.1016/j.pacs.2025.100794

N/A

0DataRank · unranked

2 citations

L. Wang, Ian S. Hagemann, Lindsay M. Kuroki, Brooke E. Sanders, Andrea R. Hagemann +4 more

Quantitative and longitudinal assessment of human placental inflammation using diffusion basis spectrum imaging

npj Women s Health(2025)10.1038/s44294-024-00049-5

N/A

0DataRank · unranked

1 citations

Wenjie Wu, Zezhen Xiang, Hansong Gao, Weina Ju, Cherilyn Uhm +7 more

SALL1 Is an Orchestrator of Uterine Receptivity in Part via Titration of Estrogen Signaling

Endocrinology(2025)10.1210/endocr/bqaf145

N/A

0DataRank · unranked

1 citations

Yan Yin, Jeannine Basta, Lynn W. Robbins, Ian S. Hagemann, Ariel Wu +4 more

Cerebellum metastasis model of HER2-positive breast cancer unveils key role of IL34-induced Arg1+ macrophages

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.06.17.660224

N/A

0DataRank · unranked

1 citations

Khooshbu Kantibhai Patel, Brandon Zhou, Yiwei Fu, Ryan Cleary, Maureen Highkin +15 more

Targeting RAD52 overcomes PARP inhibitor resistance in preclinical Brca2 -deficient ovarian cancer model

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.09.24.678351

N/A

0DataRank · unranked

0 citations

Vijayalaxmi Gupta, Bisiayo Fashemi, Moreniola Akande, Elizabeth Babu, Prasanth Thuthika +17 more

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 Trial

medRxiv(2020)10.1101/2020.03.18.20037846

N/A

0DataRank · unranked

4 citations

Katie M. Campbell, Ann Marie Egloff, Paul Zolkind, Zachary L. Skidmore, Brian Nussenbaum +39 more

Early Assessment Window for Predicting Breast Cancer Neoadjuvant Therapy Using Biomarkers, Ultrasound, and Diffuse Optical Tomography

Research Square(2020)10.21203/rs.3.rs-54759/v1

N/A

0DataRank · unranked

2 citations

Foluso O. Ademuyiwa, Catherine Young, Catherine M. Appleton, Matthew F. Covington, X. Cynthia +9 more

Prospective assessment of adjunctive ultrasound-guided diffuse optical tomography in women undergoing breast biopsy: Impact on BI-RADS assessments

European Journal of Radiology(2021)10.1016/j.ejrad.2021.110029

N/A

0DataRank · unranked

8 citations

Catherine A. Young, Ian S. Hagemann, Jingqin Luo, Cheryl R. Herman, Kimberly N. Wiele +5 more

Neoantigen DNA vaccines are safe, feasible, and capable of inducing neoantigen-specific immune responses in patients with triple negative breast cancer

medRxiv(2021)10.1101/2021.11.19.21266466

N/A

0DataRank · unranked

13 citations

S. Peter Goedegebuure, Nancy B. Myers, Tammi L. Vickery, Michael D. McLellan, Feng Gao +23 more